Publications

Perez de Castro I, Bivona TG, Philips MR, Pellicer A. Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Molecular and cellular biology. 2004. PMID: 15060167


Trever Bivona, MD, PhD

Madoff DC, Wallace MJ, Lichtiger B, Komanduri KV, Ross WA, Narvios AB, Parmley CL. Intraarterial platelet infusion for patients with intractable gastrointestinal hemorrhage and severe refractory thrombocytopenia. Journal of vascular and interventional radiology : JVIR. 2004. PMID: 15064344


Krishna Komanduri, MD

Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. Journal of the American College of Cardiology. 2004. PMID: 15028361


Matthew Gubens, MD, MS

Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 15020604


Eric Small, MD

Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. PMID: 14977818


Eric Small, MD

Zhang SQ, Yang W, Kontaridis MI, Bivona TG, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Molecular cell. 2004. PMID: 14967142


Trever Bivona, MD, PhD

Lynch HT, Coronel SM, Okimoto R, Hampel H, Sweet K, Lynch JF, Barrows A, Wijnen J, van der Klift H, Franken P, Wagner A, Fodde R, de la Chapelle A. A founder mutation of the MSH2 gene and hereditary nonpolyposis colorectal cancer in the United States. JAMA. 2004. PMID: 14871915


Ross Okimoto, MD

Bivona TG, Wiener HH, Ahearn IM, Silletti J, Chiu VK, Philips MR. Rap1 up-regulation and activation on plasma membrane regulates T cell adhesion. The Journal of cell biology. 2004. PMID: 14757755


Trever Bivona, MD, PhD

Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Annals of oncology : official journal of the European Society for Medical Oncology. 2004. PMID: 14760130


Patricia Cornett, MD

Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 14752077


Eric Small, MD

Locher CP, Witt SA, Ashlock BM, Levy JA. Evaluation of genetic immunization adjuvants to improve the effectiveness of a human immunodeficiency virus type 2 (HIV-2) envelope DNA vaccine. DNA and cell biology. 2004. PMID: 15000750


Jay Levy, MD

Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer chemotherapy and pharmacology. 2004. PMID: 15138711


Hope Rugo, MD

Damon LE, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA. Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer chemotherapy and pharmacology. 2004. PMID: 15138711


Lloyd Damon, MD

Reddy JC, Shuman MA, Aster RH. Quinine/quinidine-induced thrombocytopenia: a great imitator. Archives of internal medicine. 2004. PMID: 14744847


Marc Shuman, MD

Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. The oncologist. 2004. PMID: 15178814


Emily Bergsland, MD

Rugo HS. Bevacizumab in the treatment of breast cancer: rationale and current data. The oncologist. 2004. PMID: 15178815


Hope Rugo, MD

Philip V. Theodosopoulos, James L. Rubenstein, Michael W. McDermott. Brain Metastases from Genitourinary Cancer: Germ Cell, Testicular, Prostate and Bladder Cancer. Intracranial Metastases. 2004. PMID:


James Rubenstein, MD, PhD

Lu S, Wieder E, Komanduri K, Ma Q, Molldrem JJ. Vaccines in leukemia. Advances in pharmacology (San Diego, Calif.). 2004. PMID: 15464913


Krishna Komanduri, MD

Wilson MW, Kerlan RK, Fidelman NA, Venook AP, LaBerge JM, Koda J, Gordon RL. Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients. Radiology. 2004. PMID: 14695402


Alan Venook, MD

Eastham JA, Kelly WK, Grossfeld GD, Small EJ, Cancer and Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003. PMID: 14747042


Eric Small, MD